Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex (ENCORE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04677569
Recruitment Status : Recruiting
First Posted : December 21, 2020
Last Update Posted : August 1, 2022
Sponsor:
Information provided by (Responsible Party):
Insmed Incorporated

Brief Summary:
The main objective of this study is to evaluate the efficacy of ALIS (amikacin liposome inhalation suspension) + background regimen (azithromycin [AZI] + ethambutol [ETH]) compared to the ELC (empty liposome control) + background regimen on participant-reported respiratory symptoms at Month 13.

Condition or disease Intervention/treatment Phase
Mycobacterium Infections, Nontuberculous Drug: ALIS Drug: Azithromycin Drug: Ethambutol Drug: ELC (matching placebo for ALIS) Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 250 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact
Actual Study Start Date : April 1, 2021
Estimated Primary Completion Date : August 21, 2023
Estimated Study Completion Date : August 21, 2023


Arm Intervention/treatment
Experimental: ALIS + Background Regimen
Participants will be administered 590 mg of ALIS (amikacin liposome inhalation suspension) once daily. Participants will also be administered azithromycin 250 mg and ethambutol 15 mg/kg, once daily.
Drug: ALIS
Inhalation via nebulization over approximately 6 to 15 minutes
Other Names:
  • Amikacin liposome inhalation suspension
  • ARIKAYCE®

Drug: Azithromycin
Oral tablet
Other Names:
  • AZI
  • Zithromax

Drug: Ethambutol
Oral tablet
Other Names:
  • ETH
  • Myambutol

Placebo Comparator: ELC + Background Regimen
Participants will be administered ELC (empty liposome control), a visually matching placebo to ALIS (amikacin liposome inhalation suspension), once daily. Participants will also be administered azithromycin 250 mg and ETH (ethambutol) 15 mg/kg, once daily.
Drug: Azithromycin
Oral tablet
Other Names:
  • AZI
  • Zithromax

Drug: Ethambutol
Oral tablet
Other Names:
  • ETH
  • Myambutol

Drug: ELC (matching placebo for ALIS)
Inhalation via nebulization over approximately 6 to 15 minutes
Other Name: Empty liposome control




Primary Outcome Measures :
  1. Change from Baseline in Respiratory Symptom Score at Month 13 [ Time Frame: Baseline to Month 13 ]

Secondary Outcome Measures :
  1. Percentage of Participants Achieving Durable Culture Conversion at Month 15 [ Time Frame: Month 15 ]
  2. Change from Baseline in Fatigue Symptom Score at Month 13 [ Time Frame: Baseline to Month 13 ]
  3. Percentage of Participants Achieving Culture Conversion by Month 12 [ Time Frame: Month 12 ]
  4. Percentage of Participants Achieving Culture Conversion by Month 6 [ Time Frame: Month 6 ]
  5. Percentage of Participants Achieving Culture Conversion During Treatment [ Time Frame: Baseline to Month 12 ]
  6. Time to Culture Conversion [ Time Frame: Baseline to Month 12 ]
  7. Time to the First Negative Culture [ Time Frame: Baseline to Month 12 ]
  8. Percentage of Participants Who Develop a Mycobacterium avium Complex (MAC) Isolate with Amikacin Minimum Inhibitory Concentration (MIC) ≥ 128 μg/mL More Than One Time [ Time Frame: Baseline to Month 15 ]
  9. Percentage of Participants Achieving Culture Conversion and a Subsequent at Least one MAC Positive Culture in Agar Media or Broth Media in at Least 2 Consecutive Visits With Matching Species and Genome at Screening/ Baseline [ Time Frame: Baseline to Month 15 ]
  10. Percentage of Participants Achieving Culture Conversion and a Subsequently have at least One MAC Positive Culture in Agar Media or Broth Media in at Least 2 Consecutive Visits With Differing Species and/or Genome at Screening/ Baseline [ Time Frame: Baseline to Month 15 ]
  11. Percentage of Participants Meeting the Within-subject Meaningful Change Threshold as Reflected in Patient Reported Outcome Changes Scores Computed from Baseline in Participant-reported Symptoms [ Time Frame: Baseline to Month 15 ]
  12. Number of Participants Who Experience an Adverse Event (AEs) [ Time Frame: Baseline to Month 15 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female, ≥ 18 years of age (19 years or older in South Korea, 20 years or older in Japan).
  • Current diagnosis of MAC lung infection. MAC or mixed infection with MAC as the dominant species is allowed, with MAC as the intended organism for treatment.
  • A chest computerized tomography (CT) scan, read locally, within 6 months prior to Screening to determine presence and size of pulmonary cavities. Participants who do not have a chest CT scan within 6 months prior to Screening will be required to obtain a chest CT scan, read locally, during Screening.
  • Willingness and ability to adhere to prescribed study treatment during the study.
  • Women of childbearing potential (WOCBP) (ie, fertile following menarche and until becoming postmenopausal unless permanently sterile) and fertile men (ie, all men after puberty unless permanently sterile by bilateral orchidectomy) agree to practice a highly effective method of birth control from Day 1 to at least 90 days after the last dose. Examples of such birth controls are:

    • true abstinence (refraining from heterosexual intercourse during the entire study),
    • copper intrauterine device IUD,
    • hormonal methods (levonorgestrel-releasing intrauterine system, progestogen implant, combined oral contraceptive pill [combined with barrier method]),
    • exclusive homosexual relationship, or
    • sole male partner who has undergone surgical sterilization with confirmation of azoospermia at least 3 months post procedure.
  • Provide signed informed consent prior to administration of study drugs or performing any study related procedure.
  • Be able to comply with study drugs use, study visits, and study procedures as defined by the protocol.
  • Men with partners who are WOCBP (pregnant or non-pregnant) agree to use condoms and non-pregnant partners should practice a highly effective method of birth control.

Exclusion Criteria:

  • Diagnosis of cystic fibrosis (CF).
  • History of more than 3 MAC lung infections.
  • Received any mycobacterial antibiotic treatment for current MAC lung infection.
  • Refractory MAC lung infection, defined as having positive MAC cultures while being treated with a multidrug mycobacterial antibiotic treatment regimen for a minimum of 6 consecutive months and no documented successful treatment, defined as negative sputum culture for MAC and cessation of treatment.
  • Relapse of prior MAC lung infection, defined as positive sputum culture for MAC ≤6 months of cessation of prior successful treatment.
  • Evidence of any pulmonary cavity ≥ 2 cm in diameter, as determined by chest CT scan, read locally, within 6 months prior to Screening.
  • Radiographic finding of new lobar consolidation, atelectasis, significant pleural effusion, or pneumothorax during routine clinical care within 2 months prior to Screening.
  • Active pulmonary malignancy (primary or metastatic) or any malignancy requiring chemotherapy or radiation therapy within 1 year prior to Screening or anticipated during the study.
  • Acute pulmonary exacerbation (eg, chronic obstructive pulmonary disease (COPD) or bronchiectasis) requiring treatment with antibiotics, or corticosteroids (intravenous [IV] or oral), within 4 weeks prior to and during Screening.
  • Current smoker.
  • History of lung transplantation.
  • Prior exposure to ALIS (including clinical study).
  • Known hypersensitivity or contraindications to use to ALIS, aminoglycosides, or any of their excipients.
  • Disseminated MAC infection.
  • Administration of any investigational drug within 8 weeks prior to Screening.
  • Known or suspected acquired immunodeficiency syndromes (Human Immunodeficiency Virus (HIV) -positive, regardless of CD4 counts). Other immunodeficiency syndromes that may interfere with study participation in the opinion of the Investigator.
  • Current alcohol, medication, or illicit drug abuse.
  • Known and active COVID-19 infection.
  • Known hypersensitivity or contraindications to use to ethambutol, azithromycin (including other macrolides or ketolides), or any of their excipients per local labeling guidance.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04677569


Contacts
Layout table for location contacts
Contact: Insmed Medical Information 844-4-INSMED medicalinformation@insmed.com

Locations
Show Show 170 study locations
Sponsors and Collaborators
Insmed Incorporated
Layout table for additonal information
Responsible Party: Insmed Incorporated
ClinicalTrials.gov Identifier: NCT04677569    
Other Study ID Numbers: INS-416
2020-003079-16 ( EudraCT Number )
First Posted: December 21, 2020    Key Record Dates
Last Update Posted: August 1, 2022
Last Verified: July 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Insmed Incorporated:
Nontuberculous Mycobacterial Lung Infection
Mycobacterium avium complex
Arikayce®
Additional relevant MeSH terms:
Layout table for MeSH terms
Infections
Mycobacterium Infections
Mycobacterium Infections, Nontuberculous
Actinomycetales Infections
Gram-Positive Bacterial Infections
Bacterial Infections
Bacterial Infections and Mycoses
Azithromycin
Amikacin
Ethambutol
Anti-Bacterial Agents
Anti-Infective Agents
Antitubercular Agents